OVAL Revenue and Competitors
Employee Data
- OVAL has 30 Employees.
- OVAL grew their employee count by 30% last year.
OVAL's People
Name | Title | Email/Phone |
---|
OVAL Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 113 | 1% | N/A | N/A |
#2 | $7.5M | 592 | 52% | N/A | N/A |
#3 | $1.7M | 18 | 80% | $10.9M | N/A |
#4 | N/A | 172 | 74% | N/A | N/A |
#5 | N/A | 3 | 50% | N/A | N/A |
#6 | N/A | 77 | 8% | N/A | N/A |
#7 | $7.5M | 151 | 30% | N/A | N/A |
#8 | N/A | 49 | 26% | N/A | N/A |
#9 | N/A | 4 | 0% | N/A | N/A |
#10 | $3.5M | 16 | 33% | $5.7M | N/A |
What Is OVAL?
Inherently intelligent and communicative, the human body knows exactly what it needs to achieve its full wellness potential. As the first — and most precise — solution for improving wellness, OVAL marries this intelligence with science and AI-technology to support wellness, effectively listening to the needs of the metabolic system and interpreting them into an individualized and exacting 6 heartbeat range movement program. These physiology engineered movement programs customize cardiovascular workouts to maximize fat utilization and train the body to recover faster and more efficiently from elevated stress states. Ongoing research continues to show that improving metabolic health may help to:\n\nReduce the risk of cardiovascular disease\nOptimize fat utilization \nReduce the risks of neurodegenerative diseases, like Alzheimer’s, Parkinson’s, and ALS\nReduce the risks of cancer\nReduce systemic inflammation\nImprove the regulation of hormones, neurotransmitters, and calcium\n\nOVAL: Cultivating the strength of the human spirit, in pursuit of a life lived on purpose.
keywords:N/AN/A
Total Funding
30
Number of Employees
N/A
Revenue (est)
30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.9M | 30 | 7% | N/A |
#2 | $5M | 30 | -9% | $31M |
#3 | N/A | 30 | 30% | N/A |
#4 | $6.5M | 30 | -14% | N/A |
#5 | $2.4M | 30 | 3% | N/A |